May, 17 2019 16:34 JST

Source: Eisai

"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets


TOKYO, May, 17 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction.

"SBT Initiative" is an international joint initiative by CDP which is an international NGO operating information disclosure program related to the environment field, the UN Global Compact (UNGC), the World Wildlife Fund (WWF), and the World Resources Institute (WRI). Paris Agreement includes to keep the global average temperature rise since pre-industrial revolution to below 2degC as a long-term common global goal for GHG reduction. According to this adaptation of Paris Agreement, SBT Initiative certifies companies with ambitious targets meeting the SBT "2degC target". "SBT Initiative" certified that the following Eisai's GHG emission reduction targets are recognized as based on scientific grounds and therefore approved.

- 30% reduction of GHG emission (Scope 1 and 2) by FY2030 from FY2016
- 30% reduction of GHG emission (emission based on purchased products and services in Scope 3) by FY2030 from FY2016

Scope 1: Direct emission of GHG released into the air by the use of fossil fuel
Scope 2: Indirect emission of GHG with use of electricity and steam purchased from others
Scope 3: Indirect emission of GHG by supply chain excluding Eisai

Eisai's corporate philosophy is to give first thought to patients and their families, and increase that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will strengthen the activities for climate changes and contributes to ensure the society sustainability.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 17 2019 08:20 JST
 
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11 2019 12:59 JST
 
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 11 2019 09:04 JST
 
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
July 10 2019 12:27 JST
 
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
July 08 2019 09:31 JST
 
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18 2019 12:32 JST
 
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
June 18 2019 12:11 JST
 
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29 2019 09:05 JST
 
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16 2019 07:37 JST
 
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10 2019 12:34 JST
 
More Press release >>

Latest Press Release


More Latest Release >>